Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration

Authors:

Abstract
G Mountzios, J Remon, S Novello, N Blais, R Califano, T Cufer, A M Dingemans, S V Liu, N Peled, N A Pennell, M Reck, C Rolfo, D Tan, J Vansteenkiste, H West, B
Funding Information
  • AstraZeneca (10.13039/100004325)

This publication has 16 references indexed in Scilit: